CY1116785T1 - Χαμηλης αποτομης αποδεσμευσης πολυ-(γαλακτιδιο/γλυκολιδιο) και μεθοδοι παραγωγης πολυμερων - Google Patents

Χαμηλης αποτομης αποδεσμευσης πολυ-(γαλακτιδιο/γλυκολιδιο) και μεθοδοι παραγωγης πολυμερων

Info

Publication number
CY1116785T1
CY1116785T1 CY20151100906T CY151100906T CY1116785T1 CY 1116785 T1 CY1116785 T1 CY 1116785T1 CY 20151100906 T CY20151100906 T CY 20151100906T CY 151100906 T CY151100906 T CY 151100906T CY 1116785 T1 CY1116785 T1 CY 1116785T1
Authority
CY
Cyprus
Prior art keywords
polymer
galkalide
gycolide
production methods
low distribution
Prior art date
Application number
CY20151100906T
Other languages
English (en)
Inventor
Eric Dadey
John Middleton
Richard L Norton
Original Assignee
Tolmar Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar Therapeutics, Inc. filed Critical Tolmar Therapeutics, Inc.
Publication of CY1116785T1 publication Critical patent/CY1116785T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/88—Post-polymerisation treatment
    • C08G63/90—Purification; Drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Ένα υλικό PLG συμπολυμερούς, καλούμενο ένα υλικό PLG(p) πολυμερούς, προσαρμοσμένο για χρήση σε ένα ελεγχόμενης αποδέσμευσης σκεύασμα για ένα βιοδραστικό υλικό παρέχεται, όπου το σκεύασμα παρουσιάζει ένα μειωμένο φαινόμενο «αρχικής απότομης αποδέσμευσης» όταν εισάγεται στον ιστό ενός ασθενούς ο οποίος το έχει ανάγκη. Μία μέθοδος παρασκευής του υλικού PLG συμπολυμερούς επίσης παρέχεται, όπως επίσης μέθοδοι χρήσης.
CY20151100906T 2007-02-15 2015-10-08 Χαμηλης αποτομης αποδεσμευσης πολυ-(γαλακτιδιο/γλυκολιδιο) και μεθοδοι παραγωγης πολυμερων CY1116785T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90143507P 2007-02-15 2007-02-15
EP08725511.3A EP2115029B1 (en) 2007-02-15 2008-02-13 Low burst poly-(lactide/glycolide) and methods to produce polymers

Publications (1)

Publication Number Publication Date
CY1116785T1 true CY1116785T1 (el) 2017-03-15

Family

ID=39504385

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20151100906T CY1116785T1 (el) 2007-02-15 2015-10-08 Χαμηλης αποτομης αποδεσμευσης πολυ-(γαλακτιδιο/γλυκολιδιο) και μεθοδοι παραγωγης πολυμερων
CY20191101209T CY1122304T1 (el) 2007-02-15 2019-11-18 Χαμηλης αποτομης αποδεσμευσης πολυ-(γαλακτιδιο/γλυκολιδιο) και μεθοδοι παραγωγης πολυμερων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20191101209T CY1122304T1 (el) 2007-02-15 2019-11-18 Χαμηλης αποτομης αποδεσμευσης πολυ-(γαλακτιδιο/γλυκολιδιο) και μεθοδοι παραγωγης πολυμερων

Country Status (16)

Country Link
US (7) US9187593B2 (el)
EP (3) EP2115029B1 (el)
JP (3) JP5342459B2 (el)
CA (1) CA2678350C (el)
CY (2) CY1116785T1 (el)
DK (3) DK2115029T3 (el)
ES (3) ES2956244T3 (el)
FI (1) FI3660073T3 (el)
HK (1) HK1138303A1 (el)
HR (3) HRP20231117T3 (el)
HU (3) HUE047775T2 (el)
LT (2) LT3202814T (el)
PL (3) PL2115029T3 (el)
PT (3) PT3202814T (el)
SI (3) SI3660073T1 (el)
WO (1) WO2008100532A1 (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007084460A2 (en) 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
PL2115029T3 (pl) 2007-02-15 2016-01-29 Tolmar Therapeutics Inc Poli(laktyd/glikolid) o niskim efekcie nagłego uwalniania i sposoby wytwarzania polimerów
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
EP2309982A2 (en) * 2008-06-03 2011-04-20 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
HUE029895T2 (en) 2010-05-31 2017-04-28 Farm Rovi Lab Sa Antipsychotic injectable depot preparation
LT2394663T (lt) 2010-05-31 2022-02-10 Laboratorios Farmaceuticos Rovi, S.A. Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
CN103421172B (zh) * 2012-05-23 2016-01-20 上海现代药物制剂工程研究中心有限公司 一种生物可降解聚酯的纯化工艺
BR112015022023B1 (pt) 2013-03-11 2022-12-06 Durect Corporation Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
WO2014168134A1 (ja) * 2013-04-11 2014-10-16 三井化学株式会社 乳酸―グリコール酸共重合体の製造法またはその塩の製造法
EP3076948B1 (en) * 2013-12-06 2020-11-18 Allergan, Inc. Intracameral implant for treatment of an ocular condition
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
US11000520B2 (en) 2014-11-07 2021-05-11 Indivior Uk Limited Buprenorphine dosing regimens
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN108498456B (zh) * 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
KR20220151622A (ko) 2020-02-06 2022-11-15 오큘라 테라퓨틱스, 인코포레이티드 안질환 치료를 위한 조성물 및 방법
WO2022070010A1 (en) 2020-09-30 2022-04-07 Tolmar International Limited Biodegradable polymer delivery system for extended delivery of testosterone

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
DE3641692A1 (de) * 1986-12-06 1988-06-09 Boehringer Ingelheim Kg Katalysatorfreie resorbierbare homopolymere und copolymere
DE3708916A1 (de) 1987-03-19 1988-09-29 Boehringer Ingelheim Kg Verfahren zur reinigung resorbierbarer polyester
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
ATE168391T1 (de) 1990-04-13 1998-08-15 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare polymere, ihre herstellung und ihre verwendung
USRE37950E1 (en) * 1990-04-24 2002-12-31 Atrix Laboratories Biogradable in-situ forming implants and methods of producing the same
US6353030B1 (en) * 1990-08-01 2002-03-05 Novartis Ag Relating to organic compounds
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
EP0560014A1 (en) 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US5681873A (en) 1993-10-14 1997-10-28 Atrix Laboratories, Inc. Biodegradable polymeric composition
WO1995027481A1 (en) 1994-04-08 1995-10-19 Atrix Laboratories, Inc. Liquid delivery compositions
CA2214889C (en) 1995-03-10 2005-05-24 Hans Koll Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and a process for the production thereof
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6264970B1 (en) * 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
JP4317599B2 (ja) * 1996-06-26 2009-08-19 武田薬品工業株式会社 徐放性製剤
JP4656725B2 (ja) * 1997-10-03 2011-03-23 プロセリックス・ソルト・レイク・シティ，インコーポレーテッド 逆熱的ゲル化特性を有する生分解性低分子量トリブロックポリ（ラクチド−ｃｏ−グリコリド）−ポリエチレングリコールコポリマー
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6355657B1 (en) 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
WO2002012369A1 (fr) * 2000-08-07 2002-02-14 Wako Pure Chemical Industries, Ltd. Polymere d'acide lactique et son procede de preparation
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
JP5188670B2 (ja) * 2001-06-29 2013-04-24 武田薬品工業株式会社 徐放性組成物およびその製造法
US20060034889A1 (en) * 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
AU2005294382A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
DK1824460T3 (en) * 2004-11-10 2015-01-19 Tolmar Therapeutics Inc Stabilized polymeric delivery system
PL2079767T3 (pl) * 2006-10-11 2015-05-29 Tolmar Therapeutics Inc Wytwarzanie biodegradowalnych poliestrów z właściwościami niskiego wyrzutu przez ekstrakcję płynem nadkrytycznym
PL2115029T3 (pl) 2007-02-15 2016-01-29 Tolmar Therapeutics Inc Poli(laktyd/glikolid) o niskim efekcie nagłego uwalniania i sposoby wytwarzania polimerów

Also Published As

Publication number Publication date
FI3660073T3 (fi) 2023-09-11
US9187593B2 (en) 2015-11-17
PL2115029T3 (pl) 2016-01-29
ES2956244T3 (es) 2023-12-15
US20190209643A1 (en) 2019-07-11
SI2115029T1 (sl) 2016-01-29
HK1138303A1 (en) 2010-08-20
PT3660073T (pt) 2023-08-31
HUE047775T2 (hu) 2020-05-28
PT3202814T (pt) 2019-11-26
CA2678350A1 (en) 2008-08-21
US9561282B2 (en) 2017-02-07
US20170216395A1 (en) 2017-08-03
US20220202941A1 (en) 2022-06-30
LT3202814T (lt) 2019-12-10
WO2008100532A1 (en) 2008-08-21
HRP20192055T1 (hr) 2020-02-21
CY1122304T1 (el) 2021-01-27
HUE063170T2 (hu) 2024-01-28
DK2115029T3 (en) 2015-10-05
ES2550014T3 (es) 2015-11-03
HRP20150997T1 (hr) 2015-12-18
JP2010519218A (ja) 2010-06-03
US11717572B2 (en) 2023-08-08
DK3660073T3 (da) 2023-09-18
US11147880B2 (en) 2021-10-19
EP3202814A1 (en) 2017-08-09
PL3202814T3 (pl) 2020-01-31
SI3202814T1 (sl) 2019-12-31
EP2115029A1 (en) 2009-11-11
EP3660073B1 (en) 2023-07-12
LT3660073T (lt) 2023-10-10
US9974824B2 (en) 2018-05-22
DK3202814T3 (da) 2019-11-25
JP5342459B2 (ja) 2013-11-13
ES2755374T3 (es) 2020-04-22
PL3660073T3 (pl) 2023-12-27
EP2115029B1 (en) 2015-09-16
SI3660073T1 (sl) 2023-10-30
JP6195587B2 (ja) 2017-09-13
HRP20231117T3 (hr) 2023-12-22
JP2013224339A (ja) 2013-10-31
US10206970B2 (en) 2019-02-19
EP3202814B1 (en) 2019-10-16
HUE025842T2 (en) 2016-04-28
US20170095560A1 (en) 2017-04-06
JP5848290B2 (ja) 2016-01-27
JP2015127351A (ja) 2015-07-09
CA2678350C (en) 2015-11-17
US20180311305A1 (en) 2018-11-01
US20160106847A1 (en) 2016-04-21
PT2115029E (pt) 2015-10-26
US9655970B2 (en) 2017-05-23
US20100292195A1 (en) 2010-11-18
EP3660073A1 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
CY1116785T1 (el) Χαμηλης αποτομης αποδεσμευσης πολυ-(γαλακτιδιο/γλυκολιδιο) και μεθοδοι παραγωγης πολυμερων
WO2010103186A3 (en) Novel composite materials comprising a thermoplastic matrix polymer and wood particules
MX2012004929A (es) Articulo de tubo medico.
CY1118954T1 (el) Βιοσυμβατο και βιοδιασπωμενο συστημα στιβαδων βαθμιδωσης για την αναγεννητικη ιατρικη και την υποστηριξη των ιστων
MY169349A (en) Biodegradable, semi-crystalline, phase separated, thermoplastic multi-block copolymers for controlled release of biologically active compounds
MY165892A (en) Polymerisable material
WO2008085490A3 (en) Methods of making high-strength ndga polymerized collagen fibers and related collagen-prep methods, medical devices and constructs
WO2008139786A1 (ja) 微細針ディバイス及びその製造方法
CY1116090T1 (el) Μεθοδος για σχηματισμο γελης φιμπροϊνης μεταξης χρησιμοποιωντας κατεργασια υπερηχων
BRPI0914145A2 (pt) métodos para produzir polimerização por radical controlada, e para obter distribuição por radical atva controlada.
UA108598C2 (xx) Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
MX2009006143A (es) Sistema de canula de trocar.
ATE550050T1 (de) Medizinische geräte mit verbessertem wirkstoffreisetzungsprofil
CY1116196T1 (el) Ρευστη συνθεση περιλαμβανουσα βιοσυμβατες συνθεσεις ολιγομερους-πολυμερους
NZ729417A (en) Compositions and methods for enhancing healing and regeneration of bone and soft tissue
WO2007136936A3 (en) Dermis-derived cells for tissue engineering applications
WO2009147641A3 (en) A device and a system for delivery of biological material
MX2015008286A (es) Composiciones multipolimericas para liberación transdermica de farmaco.
BRPI1012051A2 (pt) "composição para o cuidado oral, filme de matriz polimétrica, e métodos para preparar o filme, e para tratar uma doença ou condição da cavidade oral"
ATE362776T1 (de) Quellbare hydrogelbildende polymere mit geringem feinstaubanteil
BR112014029760A2 (pt) dispositivos de distribuição de agente bioativo e métodos para fazer e usar os mesmos
PL1638535T3 (pl) Podskórne implanty o ograniczonym początkowym uwalnianiu składnika czynnego, a następnie o rozciągniętym w czasie uwalnianiu zmieniającym się liniowo
IN266731B (el)
RU2018123170A (ru) Иммуностимулирующие композиции
BR112019002352A2 (pt) polímero antimicrobiano para uso em implantes oftalmológicos